IL13RA2 and neoplasm: Notably, the efficacy of checkpoint blockade appears to depend on the specific CAR T-cell construct employed, as CAR T cells targeting EGFRvIII and IL13Rα2 induce distinct checkpoint expression profiles within the tumor microenvironment [133].